NCT00430014View on ClinicalTrials.gov

Study of Atiprimod Treatment for Patients With Advanced Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

Advanced Cancer

Interventions

DRUG

Atiprimod

Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Callisto Pharmaceuticals

All Listed Sponsors

collaborator

Callisto Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER